Brief: Lipocine Receives Updated Regulatory Guidance on LPCN 1154
06/02/2025 13:37
Feb 6 (Reuters) - Lipocine LPCN.O :
* LIPOCINE RECEIVES UPDATED REGULATORY GUIDANCE ON LPCN 1154
* LIPOCINE INC - FDA REQUIRES EFFICACY AND SAFETY STUDY FOR
LPCN
1154 NDA SUBMISSION
* LIPOCINE INC - PLANS PHASE 3 SAFETY AND EFFICACY STUDY FOR
LPCN
1154
Source text: ID:nPn78Pz7Fa
Further company coverage: LPCN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy